NeuroMetrix Inc. [NASDAQ: NURO] gained 107.17% or 10.76 points to close at $20.80 with a heavy trading volume of 87709183 shares. The company report on July 20, 2021 that NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology.
NeuroMetrix, Inc. (Nasdaq: NURO) announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults.
Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances. It affects an estimated 2 to 6 percent of the U.S. population (5 to 15 million people) and is most often diagnosed between the ages of 30 and 50. The cause of fibromyalgia remains unclear, but scientific studies point to abnormalities in the way the brain processes normal sensations and pain. Although several drugs are FDA approved for managing fibromyalgia pain, there is an unmet need for safe and effective non-pharmacological treatments.
It opened the trading session at $17.41, the shares rose to $38.67 and dropped to $15.75, the range by which the price of stock traded the whole day. The daily chart for NURO points out that the company has recorded 430.61% gains over the past six months. However, it is still -1396.4% lower than its most recent low trading price.
If we look at the average trading volume of 4.59M shares, NURO reached to a volume of 87709183 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about NeuroMetrix Inc. [NURO]:
H.C. Wainwright have made an estimate for NeuroMetrix Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 20, 2017. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on June 28, 2016, representing the official price target for NeuroMetrix Inc. stock. Previously, the target price had yet another raise to $2, while Maxim Group analysts kept a Buy rating on NURO stock.
The Average True Range (ATR) for NeuroMetrix Inc. is set at 2.79, with the Price to Sales ratio for NURO stock in the period of the last 12 months amounting to 10.71. The Price to Book ratio for the last quarter was 14.96, with the Price to Cash per share for the same quarter was set at 1.34.
Trading performance analysis for NURO stock
NeuroMetrix Inc. [NURO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 540.00. With this latest performance, NURO shares gained by 497.70% in over the last four-week period, additionally plugging by 430.61% over the last 6 months – not to mention a rise of 914.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NURO stock in for the last two-week period is set at 97.22, with the RSI for the last a single of trading hit 98.33, and the three-weeks RSI is set at 95.92 for NeuroMetrix Inc. [NURO]. The present Moving Average for the last 50 days of trading for this stock 3.75, while it was recorded at 8.11 for the last single week of trading, and 3.16 for the last 200 days.
NeuroMetrix Inc. [NURO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and NeuroMetrix Inc. [NURO] shares currently have an operating margin of -18.23 and a Gross Margin at +71.15. NeuroMetrix Inc.’s Net Margin is presently recorded at -28.36.
Return on Total Capital for NURO is now -26.00, given the latest momentum, and Return on Invested Capital for the company is -45.70. Return on Equity for this stock declined to -53.80, with Return on Assets sitting at -28.11. When it comes to the capital structure of this company, NeuroMetrix Inc. [NURO] has a Total Debt to Total Equity ratio set at 20.22. Additionally, NURO Total Debt to Total Capital is recorded at 16.82, with Total Debt to Total Assets ending up at 13.27. Long-Term Debt to Equity for the company is recorded at 8.79, with the Long-Term Debt to Total Capital now at 7.31.
Reflecting on the efficiency of the workforce at the company, NeuroMetrix Inc. [NURO] managed to generate an average of -$104,610 per employee. Receivables Turnover for the company is 17.95 with a Total Asset Turnover recorded at a value of 0.99.NeuroMetrix Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.30.
NeuroMetrix Inc. [NURO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NURO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for NeuroMetrix Inc. go to 15.00%.
An analysis of insider ownership at NeuroMetrix Inc. [NURO]
There are presently around $6 million, or 22.50% of NURO stock, in the hands of institutional investors. The top three institutional holders of NURO stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 97,663, which is approximately New of the company’s market cap and around 18.10% of the total institutional ownership; VANGUARD GROUP INC, holding 66,234 shares of the stock with an approximate value of $1.38 million in NURO stocks shares; and DIMENSIONAL FUND ADVISORS LP, currently with $0.92 million in NURO stock with ownership of nearly New of the company’s market capitalization.
Positions in NeuroMetrix Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 9 institutional holders increased their position in NeuroMetrix Inc. [NASDAQ:NURO] by around 251,903 shares. Additionally, 6 investors decreased positions by around 48,650 shares, while 1 investors held positions by with 17,013 shares. The mentioned changes placed institutional holdings at 283,540 shares, according to the latest SEC report filing. NURO stock had 6 new institutional investments in for a total of 201,526 shares, while 5 institutional investors sold positions of 46,910 shares during the same period.